Business
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris
About this update from Guardant Health, Inc.
[{"type":"text","content":" REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company’s new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building and managing pharmaceutical and biotechnology brands through all stages of commercialization, which will be invaluable as the company’s oncology portfolio expands to cover advanced and earlier stage cancers.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005443/en/Chris Freeman (Photo: Business Wire)\n“I am thrilled to welcome Chris Freeman as our new Chief Commercial Officer. Chris’s broad experience leading blockbuster products through commercialization will be essential as we continue to develop and scale our portfolio of products for advanced and early-stage cancers and effectively deploy precision oncology to improve outcomes for patients,” said Helmy Eltoukhy, Guardant Health CEO. “Chris’s leadership and business acumen will be vital as we build the commercial capabilities needed to drive growth in both existing and new market segments as we serve cancer patients across all stages of the disease.”\n\n“I am excited to join Guardant Health in their mission to improve cancer care for all patients,” said Chris Freeman. “The company has made great inroads in introducing cutting-edge new products to improve outcomes in advanced and most recently early-stage cancer, but there remains the challenge of accelerating clinical adoption so that all patients can benefit from precision oncology advancements. I am eager to work with the talented team at Guardant Health to introduce and expand access to ground-breaking new products as well as make sure that clinicians and the patients they serve are aware of how our products can help improve cancer care across the care continuum.”\n\nPrior to joining Guardant Health, Chris worked for the last ten years at Gilead Sciences, Inc. where he served most recently as Vice President of their HIV Business Unit, leading the $13 billion HIV treatment and prevention business. During the COVID-19 pandemic, Chris led the Emergency Use Authorization for Veklury (remdesivir) to treat COVID-19. Chris previously worked at Elan...